Full-Time

Associate Scientist

Mass Spectrometry

Confirmed live in the last 24 hours

AbCellera Biologics

AbCellera Biologics

501-1,000 employees

Biotechnology firm specializing in antibody therapies

Biotechnology
Healthcare

Compensation Overview

CA$60.5k - CA$75.6kAnnually

+ Bonus

Entry, Junior, Mid

Vancouver, BC, Canada

Category
Lab & Research
Life Sciences
Requirements
  • BSc in Analytical Chemistry, Biochemistry, or related field with 2-5 years of experience or MSc with 0 to 2 years of experience in an academic or industry wet lab environment
  • Experience working in areas of therapeutic protein characterization in either academia or industry
  • Proven technical ability to execute and troubleshoot experiments through rational and critical thinking
  • Familiar with electronic lab notebooks (Ex. Benchling), experimental data capture, and the associated 21 CFR part 11 compliance requirements
  • Highly organized with the ability to multitask in order to meet critical timelines
  • Outstanding communicator, team player, and relationship builder, with a demonstrated ability to build, lead, and mentor a high-performing team
Responsibilities
  • Performing MS instrument calibration and instrument maintenance
  • Designing, developing and, when necessary, qualifying LC-MS-based analytical methods in support of bioprocess development activities (cell line development, upstream/downstream process development, pharmaceutical development)
  • Performing routine analyses of samples in support of monoclonal antibody process development
  • Managing MS-based analytical requests through Electronic Lab Notebooks
  • Communicating within and across organizations to align methodology and share analytical findings
  • Researching and evaluating technological advances in the field of analytical chemistry

AbCellera specializes in discovering and developing therapeutic antibodies for various diseases. The company uses a proprietary technology platform that combines different scientific methods to identify and create antibodies efficiently. Clients, including pharmaceutical companies and research institutions, partner with AbCellera to enhance their drug development processes. Unlike many competitors, AbCellera focuses on challenging targets that traditional methods struggle to address. The company aims to accelerate the development of new medicines through collaborations, generating revenue from discovery services, licensing agreements, and its own therapeutic programs.

Company Stage

Grant

Total Funding

$620.9M

Headquarters

Vancouver, Canada

Founded

2012

Growth & Insights
Headcount

6 month growth

5%

1 year growth

0%

2 year growth

31%
Simplify Jobs

Simplify's Take

What believers are saying

  • Strategic collaborations with firms like Viking Global Investors and Biogen expand AbCellera's capabilities and market opportunities.
  • AbCellera's participation in high-profile industry conferences and presentations, such as AACR, showcases its cutting-edge research and strengthens its industry reputation.
  • The company's internal pipeline of therapeutic programs offers potential for significant breakthroughs and new treatments.

What critics are saying

  • The highly competitive and rapidly evolving biopharmaceutical market requires continuous innovation to maintain a competitive edge.
  • The recent resignation of board member Peter Thiel could lead to strategic and governance challenges.

What makes AbCellera Biologics unique

  • AbCellera's proprietary technology platform accelerates antibody discovery, making it faster and more efficient than traditional methods.
  • The company's ability to tackle challenging targets that have been difficult to address with traditional methods sets it apart in the biopharmaceutical market.
  • AbCellera's collaborative business model, which includes partnerships with leading investment firms and biotech companies, enhances its innovation and market reach.

Help us improve and share your feedback! Did you find this helpful?